Anaphylaxis to three humanized antibodies for severe asthma: a case study

Allergy, Asthma & Clinical Immunology

Norihiro Harada¹  Tomohito Takeshige¹  Koichi Jingo¹  Masahiro Torasawa¹  Tetsuhiko Asao¹  Haruhi Takagi¹  Jun Ito¹  Toshihiko Nishioki¹  Kazuhisa Takahashi¹  Tomoko Yamada¹ 

[1] Department of Respiratory Medicine, Juntendo University Faculty of Medicine and Graduate School of Medicine;

关键词: Anaphylaxis;    Humanized antibody;    Benralizumab;    Omalizumab;    Mepolizumab;   

DOI  :  10.1186/s13223-020-00446-w

来源: DOAJ

【 摘 要 】

Abstract Background Omalizumab, mepolizumab, benralizumab, and dupilumab are the currently available biologics used to treat asthma in Japan. Anaphylaxis following treatment with mepolizumab or benralizumab is considered rare. Case presentation We report the case of a 35-year-old woman with severe asthma, who experienced anaphylaxis following the administration of benralizumab, mepolizumab, and omalizumab, separately. The therapy with biologics was chosen to avoid the repeated use of systemic corticosteroids for asthma exacerbations. The mechanisms underlying anaphylaxis caused by these three biologics remain unclear. The patient’s asthma symptoms and lung function improved after treatment with bronchial thermoplasty. Conclusions To our knowledge, this is the first report of an asthmatic patient developing anaphylaxis after commencement of benralizumab, mepolizumab, and omalizumab therapy. These three biologics should be administered carefully, and patients should be monitored for anaphylaxis.

【 授权许可】

Unknown